Cardiovascular risk following cannabinoid treatment for patients with chronic pain

Back

ESC Professional Premium Access

Cardiovascular risk following cannabinoid treatment for patients with chronic pain

Session: Drug cardiotoxicity: what do we need to know?

Topic: Cardiotoxicity of Drugs

Speaker: Miss N. Nouhravesh (Durham, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Miss Nina Nouhravesh

Duke Clinical Research Institute, Durham (United States of America)

0 follower

6 more presentations in this session

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Speaker: Doctor N. Maurea (Naples, IT)

Access

Abstract

Slides

Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials

Speaker: Associate Professor M. Schmidt (Aarhus, DK)

Access

Abstract

Slides

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Speaker: Doctor N. Maurea (Naples, IT)

Access

Abstract

Slides

Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient

Speaker: Mr E. Fort (Barcelona, ES)

Access

Abstract

Slides

Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction

Speaker: Doctor N. Maurea (Naples, IT)

Access

Abstract

Slides

Access the full session

Drug cardiotoxicity: what do we need to know?

Speakers: Miss N. Nouhravesh, Doctor N. Maurea, Associate Professor M. Schmidt, Doctor N. Maurea, Mr E. Fort...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources